NASDAQ:RKDA - Arcadia Biosciences Stock Price, Forecast & News

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Arcadia Biosciences's stock reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.

Arcadia Biosciences Inc (NASDAQ:RKDA) announced its earnings results on Wednesday, November, 6th. The basic materials company reported ($2.04) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.77) by $1.27. The basic materials company earned $0.39 million during the quarter, compared to the consensus estimate of $0.31 million. Arcadia Biosciences had a negative net margin of 1,938.76% and a negative return on equity of 198.10%. View Arcadia Biosciences' Earnings History.

Arcadia Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Arcadia Biosciences.

2 brokerages have issued 1-year price objectives for Arcadia Biosciences' shares. Their forecasts range from $14.00 to $16.00. On average, they expect Arcadia Biosciences' share price to reach $15.00 in the next year. This suggests a possible upside of 201.8% from the stock's current price. View Analyst Price Targets for Arcadia Biosciences.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcadia Biosciences.

Press coverage about RKDA stock has trended somewhat positive on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arcadia Biosciences earned a news impact score of 1.3 on InfoTrie's scale. They also assigned news headlines about the basic materials company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Arcadia Biosciences.

Some companies that are related to Arcadia Biosciences include Marrone Bio Innovations (MBII), Wynnstay Group (WYN), Evogene (EVGN), China Green Agriculture (CGA), Eden Research (EDEN), Bion Environmental Technologies (BNET), SenesTech (SNES), Kiwa Bio-Tech Products Group (KWBT) and Cavitation Technologies (CVAT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Opko Health (OPK), Verastem (VSTM), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Antares Pharma (ATRS).

(RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.

Arcadia Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.44%), Oxford Asset Management LLP (0.40%), Bank of Montreal Can (0.35%) and Virtu Financial LLC (0.13%). Company insiders that own Arcadia Biosciences stock include Eric J Rey, Kevin Comcowich, Lilian Shackelford Murray, Matthew T Plavan, Sarah Reiter and Zhongjin Lu. View Institutional Ownership Trends for Arcadia Biosciences.

RKDA stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for Arcadia Biosciences.

RKDA stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Virtu Financial LLC and Geode Capital Management LLC. Company insiders that have bought Arcadia Biosciences stock in the last two years include Kevin Comcowich, Lilian Shackelford Murray, Matthew T Plavan and Sarah Reiter. View Insider Buying and Selling for Arcadia Biosciences.

Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RKDA stock can currently be purchased for approximately $4.97.

Arcadia Biosciences has a market capitalization of $42.99 million and generates $1.46 million in revenue each year. The basic materials company earns $-13,480,000.00 in net income (profit) each year or ($5.35) on an earnings per share basis. Arcadia Biosciences employs 44 workers across the globe.View Additional Information About Arcadia Biosciences.

The official website for Arcadia Biosciences is http://www.arcadiabio.com/.

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]